Yusheng Han Purchases 210,000 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 210,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were purchased at an average cost of $9.25 per share, for a total transaction of $1,942,500.00. Following the completion of the transaction, the director directly owned 17,907,436 shares of the company’s stock, valued at approximately $165,643,783. This represents a 1.19% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The shares were acquired at an average price of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The shares were bought at an average price of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The stock was bought at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $9.00 per share, for a total transaction of $999,990.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Stock Performance

Shares of BNR stock opened at $9.82 on Friday. The firm has a 50 day moving average price of $12.35 and a two-hundred day moving average price of $19.96. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $103.31 million, a PE ratio of -11.98 and a beta of 1.32. Burning Rock Biotech Limited Sponsored ADR has a 12-month low of $3.23 and a 12-month high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $19.21 million.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on BNR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On Burning Rock Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the business. Crcm LP boosted its stake in shares of Burning Rock Biotech by 121.8% in the fourth quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after buying an additional 269,851 shares during the period. Marshall Wace LLP acquired a new stake in Burning Rock Biotech during the fourth quarter worth approximately $220,000. Prospera Financial Services Inc increased its stake in Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after acquiring an additional 6,430 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after acquiring an additional 4,290 shares during the period. 30.03% of the stock is currently owned by institutional investors and hedge funds.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.